Epidemiology and Exposure Patterns

Caffeine is one of the most widely consumed psychoactive substances. Clinically important poisoning is far less common than routine exposure, but concentrated powders, tablets, pre-workout products, and multi-ingredient supplements can deliver gram-level doses quickly. Intentional self-poisoning and dosing errors account for a disproportionate share of severe cases.

The 2024 National Poison Data System recorded more than 2 million human poison exposures overall; poison-center data remain useful for surveillance, but caffeine-specific severity is better characterized by case series and published severe-poisoning cohorts. [1,3]

• Concentrated caffeine products are more strongly associated with severe and fatal poisoning than ordinary beverages.

• Product labels may list caffeine per serving rather than total container content; powders create additional dosing uncertainty.

• Coingestants can alter both the clinical picture and caffeine clearance.

Toxicokinetics

Mechanisms of Toxicity

At ordinary concentrations, caffeine primarily antagonizes adenosine receptors. With increasing concentrations, catecholamine release, phosphodiesterase inhibition, altered intracellular calcium handling, and other high-dose mechanisms become more important.

The result is a mixed neurologic, cardiovascular, and metabolic toxidrome rather than a simple stimulant effect. [2,4]

• Cardiovascular: sinus tachycardia, supraventricular tachycardia, ventricular ectopy, ventricular tachycardia/fibrillation, blood-pressure instability, and shock.

• Neurologic: anxiety, agitation, tremor, hyperreflexia, confusion, seizures, and coma.

• Metabolic: intracellular potassium shift, hyperglycemia, lactic/metabolic acidosis, leukocytosis, and occasionally hypophosphatemia or other electrolyte abnormalities.

• Musculoskeletal/renal: rhabdomyolysis and secondary acute kidney injury in severe or prolonged toxicity.

Dose and Serum Concentration Interpretation

Do Not Convert These Ranges Into Hard Treatment Thresholds

The relationship among reported dose, serum concentration, symptoms, and outcome is highly variable. Recent reviews emphasize that no single dose or caffeine concentration can determine prognosis or mandate a specific therapy by itself. [1,2]

Reported Acute Dose

Serum Caffeine Concentration

Unit conversion: 1 mg/L = 1 µg/mL. To convert caffeine from mg/L to µmol/L, multiply by approximately 5.15.

Clinical Presentation

Evaluation

Assess the estimated dose, formulation, time of ingestion, intent, coingestants, baseline cardiac disease, pregnancy status, and medications that may alter CYP1A2 metabolism.

Do not delay treatment while waiting for a serum caffeine concentration.

Recommended evaluation for clinically important exposures:

• Continuous ECG/telemetry; obtain a 12-lead ECG and repeat if symptoms or rhythm change.

• Serial vital signs, mental status, urine output, and temperature.

• Basic/comprehensive metabolic panel with potassium, bicarbonate, glucose, renal function, calcium, and magnesium; add phosphate when severe toxicity is present.

• Blood gas and lactate for moderate/severe poisoning or hemodynamic instability.

• Creatine kinase and urinalysis when prolonged agitation, seizures, hyperthermia, or rhabdomyolysis is suspected.

• Serum caffeine concentration when available, ideally serially in severe poisoning; management must not depend on immediate availability.

• Coingestant testing based on history and presentation. For intentional self-poisoning or an unreliable/uncertain history, obtain acetaminophen and salicylate concentrations unless the exposure context clearly excludes them; caffeine may be present in combination products and coingestants may dominate the toxidrome. [PP/E3]

Serum potassium is inversely correlated with caffeine concentration in observational data.

A small 2026 retrospective prediction model using heart rate, bicarbonate, and potassium showed promising discrimination for severe intoxication, but it requires external validation and should not be treated as a stand-alone rule. [5,6]

Risk Stratification

High-Risk Features

High-risk features include:

• persistent or worsening tachycardia;

• ventricular ectopy or dysrhythmia;

• hypotension;

• K <3.0 mEq/L or rapidly falling potassium;

• significant metabolic/lactic acidosis;

• recurrent vomiting;

• altered mental status;

• seizure;

• rising CK;

• massive or uncertain concentrated-product ingestion;

• very high or rising caffeine concentration;

• any need for vasopressor, mechanical ventilation, or extracorporeal support.

No single feature is sufficient in isolation.

Risk should be reassessed serially because patients may deteriorate quickly or, after massive overdose, remain toxic much longer than the usual caffeine half-life.

Management

1. Initial Stabilization

• Airway and breathing: provide oxygen and ventilatory support as clinically indicated. Intubate for inability to protect the airway, refractory seizures, severe agitation requiring deep sedation, respiratory failure, or peri-arrest physiology.

• Circulation: establish IV access, continuous cardiac monitoring, and frequent blood-pressure assessment. In severe cases, consider arterial monitoring and early bedside echocardiography to define the shock phenotype.

• Agitation/tremor: benzodiazepines are first-line and can reduce catecholamine-driven symptoms. [Strong/E3]

• Early consultation: involve a poison center/medical toxicologist for significant toxicity; involve nephrology early when extracorporeal therapy may be required. In refractory shock or malignant arrhythmia, contact an ECMO-capable center early rather than after prolonged arrest. [Conditional/E3]

2. Gastrointestinal Decontamination

Activated charcoal should not be automatic for every caffeine exposure. Current toxicology recommendations emphasize individualized use based on poison, dose, time, expected severity, airway status, and available alternatives. [7,8]

• Single-dose activated charcoal: consider as early as possible after a potentially toxic ingestion if the airway is intact or protected. Expected benefit is greatest within about 1 hour, but selected large ingestions may still justify later administration because ongoing gastrointestinal absorption is possible. [Conditional/E2]

• Typical dose: adults 50 g; children approximately 1 g/kg, commonly capped at 50 g, adjusted to local poison-center protocol.

• Additional charcoal: may be considered after a massive tablet ingestion when ongoing gastrointestinal drug burden is suspected, but evidence specific to caffeine is limited. Routine multiple-dose charcoal solely to enhance systemic caffeine elimination is not established. [Conditional/E3]

• Gastric lavage: do not use routinely. It may be considered only exceptionally after a very recent, potentially fatal ingestion when anticipated benefit outweighs risk, the airway is protected, and a medical toxicologist/poison center supports the intervention. [9] [Strong/E2]

• Do not induce emesis.

3. Mild to Moderate Toxicity

• Quiet environment, oral or IV fluids as clinically indicated, and serial reassessment.

• Benzodiazepines for clinically important tremor, anxiety, agitation, or marked sympathomimetic features.

• Antiemetic therapy for persistent vomiting, for example ondansetron.

• Recheck potassium, bicarbonate, magnesium, glucose, and ECG when symptoms are persistent or worsening.

• Escalate care promptly if hypotension, significant dysrhythmia, worsening metabolic abnormalities, altered mental status, or seizures develop.

4. Dysrhythmias and Marked Tachycardia

Unstable rhythms require standard resuscitation, synchronized cardioversion, or defibrillation as appropriate; concurrently correct hypokalemia, hypomagnesemia, acid-base abnormalities, hypoxia, and agitation.

• For severe sinus tachycardia or tachydysrhythmia producing hemodynamic compromise, a short-acting beta blocker such as esmolol may be considered with close monitoring and expert toxicology/cardiovascular input. Case literature also describes propranolol and landiolol, but comparative evidence is absent. [10]

  Expert-practice dosing example, not a caffeine-specific evidence-derived regimen: esmolol infusion 25–50 mcg/kg/min initially, titrated cautiously to effect; minimize or omit a loading bolus when hypotension or shock is present. [Conditional/E3; dosing PP/E3]

• Beta blockade is not a routine substitute for vasopressor therapy in an undifferentiated hypotensive patient. It is most rational when excessive tachycardia/tachydysrhythmia appears to be reducing cardiac output.

• Adenosine: because caffeine antagonizes adenosine receptors, adenosine may have reduced efficacy. If otherwise indicated for a regular narrow-complex tachycardia, use standard ACLS/PALS dosing but be prepared for nonresponse or recurrence; do not delay broader stabilization or escalation. [2,4] [Conditional/E3]

• Amiodarone, lidocaine, procainamide, magnesium, and electrical therapy have been used in severe cases; no caffeine-specific comparative trial establishes a preferred antiarrhythmic.

• Persistent or recurrent malignant dysrhythmia despite initial resuscitation is a strong trigger for urgent hemodialysis and consideration of VA-ECMO capability. [11–13] [Strong/E1]

5. Hypotension and Shock

• Give isotonic crystalloid judiciously when volume responsive; avoid repeated empiric boluses when shock is clearly cardiogenic or fluid unresponsive.

• Norepinephrine is a reasonable first vasopressor for persistent hypotension. Phenylephrine or vasopressin may be considered according to the hemodynamic phenotype and local critical-care practice. [Conditional/E3]

• If profound tachycardia is contributing to low cardiac output, cautious short-acting beta blockade may paradoxically improve hemodynamics, but this is case-based and requires close monitoring. [10]

• For shock refractory to conventional therapy, move rapidly toward extracorporeal caffeine removal and evaluate for mechanical circulatory support rather than serial medication escalation alone. [11–13] [Strong/E1]

6. Seizures and Severe Agitation

• Benzodiazepines are first-line for seizures. [Strong/E3]

• Use phenobarbital or propofol for recurrent or refractory seizures, with airway management as needed. [Conditional/E3]

• Treat hyperthermia aggressively with external cooling and control of muscular activity.

• Do not rely on phenytoin as primary therapy for toxin-induced seizures. [Strong/E3]

7. Electrolyte and Metabolic Abnormalities

• Hypokalemia: replete potassium judiciously, particularly when K is markedly low or dysrhythmia is present. Because the deficit is often substantially redistribution-driven, use frequent serial measurements and avoid uncontrolled over-replacement. As adrenergic redistribution resolves, serum potassium can rebound and rebound hyperkalemia may occur; continue serial potassium monitoring during recovery and after extracorporeal therapy. [2,4] [Strong/E2]

• Magnesium: correct hypomagnesemia and consider magnesium in ventricular dysrhythmia when clinically appropriate.

• Acidosis: correct shock, seizures, hypoxia, and other drivers. Sodium bicarbonate is not a caffeine-specific antidote; reserve it for standard indications such as severe acidemia or a coingestant causing sodium-channel blockade.

• Rhabdomyolysis: monitor CK, renal function, potassium, phosphate, calcium, urine output, and treat with appropriate fluid/electrolyte management.

Enhanced Elimination: Hemodialysis and Other Extracorporeal Therapies

Caffeine is highly amenable to extracorporeal removal because it has a relatively small volume of distribution, low protein binding, and substantial aqueous solubility.

The best recent evidence remains observational, but a 2025 case-review analysis and 2026 multicenter/retrospective data support early consideration of extracorporeal blood purification in severe poisoning. [1,11–13] Recent comparative clinical data show substantially greater caffeine clearance with intermittent hemodialysis than continuous kidney replacement therapy, while continuous therapy may remain useful in unstable patients. PubMed

For general extracorporeal principles, see Hemodialysis in Poisoning: A Comprehensive Guide for Healthcare Providers.

Strongly Consider Hemodialysis When One or More of the Following Are Present

• Life-threatening or refractory ventricular dysrhythmia

• Refractory shock

• Recurrent or refractory seizures

• Cardiac arrest with ongoing toxicity

• Severe or worsening metabolic/lactic acidosis despite resuscitation

• Rapidly worsening multiorgan toxicity

• Potentially lethal/massive ingestion with a severe clinical trajectory

Concentrations ≥80 mg/L are associated with severe toxicity in observational data and strengthen concern.

A serum caffeine concentration ≥140 mg/L has been proposed as a criterion for initiating hemodialysis in severe poisoning, but this threshold is not prospectively validated and no concentration should be the sole indication. Clinical trajectory governs. [1,5,6,11–13] [Strong/E1] The ≥140 mg/L proposal originates from retrospective clinical data rather than a validated universal decision rule. PubMed

Do not delay dialysis solely to obtain a caffeine concentration if the patient has a clearly severe course.

Conversely, an isolated concentration without significant clinical toxicity should not automatically mandate dialysis.

The ≥140 mg/L criterion proposed by Yoshizawa et al. is study-derived and has not been prospectively validated. [13] [Strong/E1]

Post-Dialysis Monitoring and Repeat Treatment

Continue intensive monitoring after apparent stabilization.

Severe cases have developed recurrent or prolonged toxicity after dialysis, potentially related to delayed gastrointestinal absorption, nonlinear kinetics, organ dysfunction, or accumulation of active metabolites.

A 2026 case documented recurrent cardiac arrest after initial hemodialysis despite a much lower caffeine concentration, with re-elevation of active metabolites; another 2025 report described a prolonged toxidrome requiring repeated hemodialysis. [16,17]

• Repeat serum caffeine concentrations when available and clinically useful.

• Recheck potassium, bicarbonate, lactate, ECG/rhythm burden, CK, renal function, and hemodynamics.

• Consider repeat IHD or continued extracorporeal therapy if severe toxicity persists or recurs. [Conditional/E3]

Mechanical Circulatory Support

VA-ECMO is not routine caffeine therapy, but it can function as a bridge to toxin removal when severe poisoning produces refractory ventricular fibrillation, cardiac arrest, or circulatory collapse.

Successful cases combine rapid mechanical support with hemodialysis rather than using ECMO as a substitute for toxin removal. [14,15] [Conditional/E3]

Operational Point

In a massive caffeine ingestion with recurrent malignant ventricular dysrhythmia or refractory shock, early transfer/contact with an ECMO-capable center may be more valuable than waiting until prolonged resuscitation has failed.

Antidote

There is no specific antidote for caffeine poisoning.

Treatment is supportive, targeted to the dominant physiology, and supplemented by extracorporeal removal in severe cases.

Disposition and Observation

Refer to an Acute-Care Facility

• Any intentional self-harm ingestion or malicious administration, regardless of reported dose. [Strong/E3]

• Any patient with persistent vomiting, marked agitation, palpitations with significant tachycardia, syncope, altered mental status, seizure, hypotension, or dysrhythmia.

• Any substantial or uncertain ingestion of concentrated caffeine powder/tablets, especially when the amount cannot be verified.

• Patients with clinically important cardiac disease, significant coingestants, or circumstances that make reliable home observation impossible.

No universal modern out-of-hospital mg/kg referral threshold for caffeine has been prospectively validated.

When a local poison-center protocol is unavailable, ≥30 mg/kg may be used as a conservative operational referral default, but it should not be interpreted as the lowest toxic dose or as a validated boundary between safe and dangerous exposure. [PP/E3]

Emergency Department Observation

For a potentially toxic immediate-release ingestion in an asymptomatic patient with a normal ECG and reassuring laboratory findings, approximately 6 hours of observation is a reasonable operational minimum, but this is an expert-practice interval rather than a validated caffeine-specific rule.

Observe longer for:

• massive ingestion;

• persistent symptoms;

• delayed or unknown ingestion time;

• extended-release or uncertain formulations;

• coingestants;

• electrolyte abnormalities;

• rising serum caffeine levels.

[PP/E3]

Critical-Care Admission

• Sustained or recurrent dysrhythmia beyond uncomplicated sinus tachycardia

• Hypotension, shock, vasopressor requirement, or significant cardiac dysfunction

• Seizure, altered mental status, need for intubation, severe agitation requiring deep sedation, or hyperthermia

• Marked hypokalemia or metabolic/lactic acidosis accompanied by significant symptoms or a worsening trajectory

• Need for hemodialysis, CKRT, or mechanical circulatory support

• Massive poisoning with a high likelihood of delayed/recurrent toxicity even after initial stabilization

Do not make ICU disposition depend solely on K <2.9 mEq/L** or **caffeine >50 mg/L.

Those findings may support severity assessment but are not validated stand-alone ICU criteria.

Special Considerations

Coingestants and Drug Interactions

Coingestants may change caffeine kinetics or dominate the toxidrome.

Mexiletine has been reported to substantially reduce endogenous caffeine clearance in a severe overdose, prolonging toxicity and increasing the importance of extracorporeal removal. [18]

• Check the ingredient list of analgesics, cold products, pre-workout supplements, energy products, and combination tablets rather than assuming the exposure is caffeine alone.

• Consider CYP1A2-modifying drugs and hepatic dysfunction when toxicity is more prolonged than expected.

Pediatric Exposures

Use weight-based dose estimates cautiously.

Children can develop clinically important toxicity after concentrated caffeine products, but exact pediatric dose-response thresholds are not sufficiently validated to replace poison-center assessment.

Intentional exposures, symptomatic children, concentrated-product ingestion, or uncertain doses warrant a low threshold for medical evaluation. [PP/E3]

Neonatal caffeine citrate medication errors require a separate pathway because doses may be expressed as caffeine citrate rather than caffeine base.

Caffeine citrate 20 mg/mL is equivalent to caffeine base 10 mg/mL.

Do not apply this acute-ingestion algorithm without neonatal/pediatric toxicology input. [19] [PP/E3]

Current U.S. caffeine citrate labeling confirms this 2:1 caffeine-citrate-to-caffeine-base concentration relationship. DailyMed

Pregnancy

Caffeine crosses the placenta and maternal elimination is prolonged later in pregnancy.

Acute poisoning should be managed according to maternal severity, with early obstetric consultation for clinically significant poisoning; maternal stabilization remains the priority.

Clinical Pitfalls to Avoid

• Treating 30 mg/kg as a validated toxicity cutoff or universal referral boundary.

• Calling >50 mg/L “consistently toxic” or >80 mg/L automatically fatal without clinical context.

• Delaying dialysis in a crashing patient while waiting for a caffeine concentration.

• Using gastric lavage routinely because the ingestion is large.

• Using beta blockade reflexively in undifferentiated hypotension without defining the hemodynamic problem.

• Overcorrecting redistribution-related hypokalemia without frequent reassessment.

• Assuming toxicity is over immediately after one dialysis session.

• Failing to identify active coingestants or products with multiple caffeine-containing ingredients.

Evidence Limitations

There are no prospective controlled treatment trials that define an optimal caffeine-poisoning algorithm, and no major toxicology society has published a caffeine-specific comprehensive treatment guideline.

Much of the severe-poisoning literature consists of case reports, case series, retrospective cohorts, and toxicokinetic analyses.

The 2025 review of 216 published cases is the largest synthesis to date but explicitly concludes that definitive treatment recommendations cannot be derived from the available evidence. [1] PubMed

Accordingly, this guideline deliberately labels concentration and dose values as risk markers rather than absolute thresholds.

Recommendations for beta blockade, hemodialysis, repeated extracorporeal therapy, and VA-ECMO should be individualized with poison-center/medical-toxicology and relevant critical-care specialists.